The pretreatment circulating albumin-to-fibrinogen ratio in patients with non-small cell lung cancer: a simple, economical, and effective biomarker

Lung cancer is among the most prevalent malignant diseases and the leading cause of cancer-related death worldwide. Disease progression in patients with various types of carcinomas, including lung cancer, is dependent on an intricate interaction among the tumor, host inflammatory response, and nutritional status. There is substantial evidence that the systemic inflammatory response and nutritional status of patients with carcinomas are important predictors of the outcome. The roles of biochemical or hematological markers, such as hypoalbuminemia, elevated C-reactive protein (CRP) levels, or others, have been studied by many researchers.